

---

## BIOGRAPHICAL SKETCH

---

NAME: Diego Luigi Cortinovis (PI)

eRA COMMONS USER NAME: N/A

POSITION TITLE: Medical Oncology Associate Professor / MD at Fondazione IRCCS San Gerardo dei Tintori Monza, Italy

---

### EDUCATION/TRAINING

---

| INSTITUTION AND LOCATION                                                                         | DEGREE<br>(if applicable)      | Completion Date<br>MM/YYYY | FIELD OF STUDY                |
|--------------------------------------------------------------------------------------------------|--------------------------------|----------------------------|-------------------------------|
| 1998–2003, Medicine University, Milan (Italy).<br>1991–1997, Medicine University, Milan (Italy). | Oncology Specialist            | 11/2003                    | Medical Oncology              |
|                                                                                                  | Bachelor's degree              | 10/1997                    | Medicine and Surgery          |
| 1987-1991 Scientific High School "S. Allende" Milan, (Italy)                                     | High school scientific diploma | 07/1991                    | High school scientific Lyceum |

### A. Personal Statement

**Diego Cortinovis** MD is, since 2008, vice-director at the oncology unit and, from 03/2021 Head Oncology Unit and Lung Unit at Fondazione IRCCS San Gerardo dei Tintori, in Monza, Italy, part of the University of Milan Bicocca. Diego Cortinovis MD has developed his oncology career within institutions of high scientific and clinical standing, including the National Cancer Institute of Milan, collaborating over the years with both national and international research groups. He has achieved the role of a national Key Opinion Leader in the field of lung cancer and has promoted innovative research areas, also in pleural malignancies, focusing on the evaluation and treatment of advanced disease through novel therapies.

He has further expanded his research activity to other areas of Medical Oncology, including gastrointestinal and breast cancers as well as supportive care, publishing as author and contributor in national studies and collaborating within national multidisciplinary groups.

Finally, he has built solid managerial and leadership experience in coordinating multidisciplinary teams, obtaining certificates from executive courses at SDA Bocconi School of Management and serving as deputy coordinator of the institutional multidisciplinary lung cancer group (GOI-P).

His main research interests include thoracic malignancies, lung cancer, mesothelioma, and supportive care.

### B. Positions, Scientific Appointments and Honors

#### Positions and Employment

2003-2008 Solid Tumor Oncologist. Medical Oncology at the National Cancer Institute of Milano, Italy

2008-2017 Solid tumor Oncologist of the Medical Oncology Unit, ASST Monza, San Gerardo Monza, Italy

2017-today Director of Lung Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

2021-today Director of the Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

#### Other Experience and Professional Memberships

2000-2006 Research fellow at NCI, Milan under the supervision of E. Bajetta

2003-2008 Regional Member of the Board, Italian Association Medical Oncology (AIOM)

2009-today European Society Medical Oncology (ESMO) Member

2009-today International Association for the Study of Lung Cancer (IASLC) member  
2021-today Member of the Board, Italian Group Oncological Clinical Research (GOIRC)

### **Committees Participation:**

**Scientific Member:** GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), TYME (Network on tympic cancer),  
MET-I (Mesothelioma Team Italy)

**Topic Advisory Panel:** EORTC Lung Cancer

### **C. Contributions to Science**

A. Principal Investigator and Co-Investigator in different clinical trials since 2003. His primary interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in pleural mesothelioma, as well as translational research related to predictive biomarkers. He has been involved in different key trials investigating new approaches in treatment of advanced stage of disease like maintenance therapy, treatment with targeted therapies and immunotherapy as well as supportive care (CINV/CINP). In last three years, he has been involved in >50 both interventional and observational clinical trials.

- a. Celio L, **Cortinovis D**, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). *Sci Rep.* 2023 Jan 23;13(1):1257. doi: 10.1038/s41598-023-28464-9.
- b. Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez Iranzo P, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce-Aix S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Remon Masip J, Raimbourg J, Terrisse S, Russo A, **Cortinovis D**, Rochigneux P, Pinato DJ, Cortellini A, Leone C, Gazzah A, Ghigna MR, Ferrara R, Dall'Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. *J Thorac Oncol.* 2023 Jan 13:S1556-0864(22)01994-3. doi: 10.1016/j.jtho.2022.12.018.
- c. Tabbò F, Muscarella LA, Gobbi E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, **Cortinovis D**, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, Righi L. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. *Eur J Cancer.* 2022 Oct;174:200-211. doi: 10.1016/j.ejca.2022.07.026.
- d. Banna GL, Tiseo M, **Cortinovis DL**, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1  $\geq 50\%$  metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer.* 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256.

B. He is an important contributor of Italian non for profit research. He participates as principal investigator to many trials promoted by:

- GOIRC (2021-2022): "Phase II, open label, single arm, multicenter study to assess the activity and safety of Alectinib as Neo-adjuvant therapy in patients with anaplastic lymphoma kinase-positive (ALK+) locally advanced Stage III Non-Small Cell Lung Cancer". "Phase II, multicentric, single arm trial, with durvalumab (MEDI 4736) in association with carboplatin and etoposide for 4 cycles, followed by maintenance with durvalumab in patients with lung cells neuroendocrine cancer.
- Translational Research Foundation (2020-2022) Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Phase II, two-cohorts, randomized trial comparing standard of care versus immune-

based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab (MEDI4736).

- University of Pavia (Prof Filippi): “An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypofractionated RT and maintenance immunotherapy for stage III unresectable NSCLC “

In 2022, he activated a direct collaboration with the clinical and research network on tympic cancer (TYME)

- a. Filippi AR, Agustoni F, Arcangeli S, **Cortinovis D**, Ferrari A, Cicognini D, Saddi J, Klersy C, Pedrazzoli P, Malapelle U, Grossi F. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial. Clin Lung Cancer. 2023 Jan 20:S1525-7304(23)00007-4. doi: 10.1016/j.clcc.2022.12.015.
- b. Canova S, Ceresoli GL, Grosso F, Zucali PA, Gelsomino F, Pasello G, Mencoboni M, Rulli E, Galli F, De Simone I, Carlucci L, De Angelis A, Belletti M, Bonomi M, D'Aveni A, Perrino M, Bono F, **Cortinovis DL**; DIADEM groupD. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. ESMO Open. 2022 Dec;7(6):100644. doi: 10.1016/j.esmoop.2022.100644.
- c. **Cortinovis D**, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M; ATREUS investigators Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clin Lung Cancer. 2021 Jul;22(4):361-370.e3. doi: 10.1016/j.clcc.2020.06.028.
- d. Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzuttilo EG, Bartoli G, Baldessari C, Novello S, Bria E, **Cortinovis DL**, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023.

C. He collaborates as an expert consultant and key opinion leader for pharmaceutical companies.

- a. Leighl NB, Paz-Ares L, Abreu DR, Hui R, Baka S, Bigot F, Nishio M, Smolin A, Ahmed S, Schoenfeld AJ, Daher S, **Cortinovis DL**, Di Noia V, Linardou H, Gainor JF, Dutcus C, Okpara CE, Deng X, Kush D, Arunachalam A, Song A, Cho BC. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. J Thorac Oncol. 2025 Oct;20(10):1489-1504. doi: 10.1016/j.jtho.2025.05.020.
- b. Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, **Cortinovis D**, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Högländer E, Connors M, Biggane AM, Vollen HK, Peters S. *First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study*. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2
- c. Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, **Cortinovis D**, Migliorino MR, Delmonte A, Sánchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148.
- d. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, **Cortinovis D**, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollin H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6.

- e. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, **Cortinovis DL**, Barlesi F, Yu W, Matheny C, Ballinger M, Park K. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. *J Thorac Oncol*. 2021 Jan;16(1):140-150. doi: 10.1016/j.jtho.2020.09.022.
  - f. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, **Cortinovis D**, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X.
- D. He is the founder of the multidisciplinary group for thoracic cancers at Fondazione IRCCS San Gerardo dei Tintori, Monza. He coordinates the weekly activities of the group, involving pathologists, radiotherapists, pulmonologists, and radiologists.
- a. Canova S, Arcangeli S, **Cortinovis DL**. A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non-Small Cell Lung Cancer? *JAMA Oncol*. 2022 Oct 13. doi: 10.1001/jamaoncol.2022.4442
  - b. Gnagnarella P, Muzio V, Caini S, Raimondi S, Martinoli C, Chiocca S, Miccolo C, Bossi P, **Cortinovis D**, Chiaradonna F, Palorini R, Facciotti F, Bellerba F, Canova S, Gandini S. Vitamin D Supplementation and Cancer Mortality: Narrative Review of Observational Studies and Clinical Trials. *Nutrients*. 2021 Sep 21;13(9):3285. doi: 10.3390/nu13093285.
  - c. Arizio F, Bonardi A, **Cortinovis D**, Costanzo A, Cristinziano A, Delle Monache L, Landolfi R, Lettino M, Luppi F, Petrangolini T, Tassielli D. Project R. Evolution for improving clinical research in Italy: challenges and strategies. *Curr Med Res Opin*. 2022 Sep;38(9):1631-1639. doi: 10.1080/03007995.2022.2091332.
  - d. Orlandi R, Bono F, **Cortinovis DL**, Cardillo G, Cioffi U, Guttadauro A, Pirondini E, Canova S, Cassina EM, Raveglia F Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold. *J Clin Med*. 2022 Jun 6;11(11):3225. doi: 10.3390/jcm11113225.
- D. He actively collaborates within a UNIMIB research group focused on clonal evolution in lung cancer, mechanisms of resistance to TKIs, characterization of persister cells, and the assessment of minimal residual disease.
- a. Crippa V, Cordani N, Villa AM, Malighetti F, Villa M, Sala L, Aroldi A, Piazza R, **Cortinovis D**, Mologni L, Ramazzotti D. Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. *NPJ Precis Oncol*. 2025 Aug 18;9(1):291. doi: 10.1038/s41698-025-01088-0
  - b. Villa M, Malighetti F, Sala E, Sharma GG, Arosio G, Gemelli M, Manfroni C, Fontana D, Cordani N, Meneveri R, Zambon A, Piazza R, Pagni F, **Cortinovis D**, Mologni L. *New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients*. *NPJ Precis Oncol*. 2024 Mar 6;8(1):29. doi: 10.1038/s41698-024-00498-w
  - c. Villa M, Sharma GG, Manfroni C, **Cortinovis D**, Mologni L. *New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer*. *Cancers (Basel)*. 2021 Oct 14;13(20):5149. doi: 10.3390/cancers13205149
  - d. Sharma GG, **Cortinovis D**, Agustoni F, Arosio G, Villa M, Cordani N, Bidoli P, Bisson WH, Pagni F, Piazza R, Gambacorti-Passerini C, Mologni L. *A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib*. *J Thorac Oncol*. 2019 Nov;14(11):e257-e259 doi: 10.1016/j.jtho.2019.06.028

### **Complete List of Published Work:**

<https://pubmed.ncbi.nlm.nih.gov/?term=cortinovis+d&sort=date>